James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

TVs: Great to Watch, Terrible to Invest In

Black Friday's popular mega-deals on TVs illustrates one of several problems dogging Japanese consumer tech companies.

Before You Hate Walmart and Love Target …

In Q3 earnings, Walmart missed and Target beat. Fair's fair. But what if analyst expectations were unfair and obscured other key facts?

Recreation Stocks Are Runnin’ on Fun … and the Zombiepocalypse

Whether it's preparing for the end of the world or a new yoga class, these five trends are carrying recreation stocks this year -- and should stick around for 2013.

My Brilliant Biotech Move for 2012

An overly helter-skelter year in the world of biotech stocks has been a stark reminder of a basic lesson that isn't followed enough: Keep it simple.

Monster Beverage Isn’t As Scary As It Looks

Monster shares have taken a beating in the wake of a recent lawsuit against the company and an earnings miss, but the drink-maker has good growth prospects.

Be Careful When Comparing Amazon to Netflix

While pundits are caught up in comparing Amazon's Prime streaming service to Netflix's, the argument for both stocks doesn't lie in which service is better.

2 to Buy, 2 to Sell in Precious Metals

Competition is about to get fierce in the gold & silver space -- here are two winners and two losers for the coming secular shift.

Drugstores or Benefit Managers: Who’s Holding the Cards?

CVS and Walgreen reported vastly different quarters today. Is it a sign of where there's money to be made in the future?

3 Reasons Why Starbucks Stock Will Be Even Better in 2013

Starbucks' plans for Asian expansion, as well as its progress on the technological front, set SBUX shareholders up for a big 2013.

3 Netflix Problems That Carl Icahn Can’t Fix

Carl Icahn might be able to get more value out of Netflix stock, but he's going to have to do it in the face of three obstacles he can't control.